TY - JOUR
T1 - DNase-active TREX1 frame-shift mutants induce serologic autoimmunity in mice
AU - Sakai, Tomomi
AU - Miyazaki, Takuya
AU - Shin, Dong Mi
AU - Kim, Yong Soo
AU - Qi, Chen Feng
AU - Fariss, Robert
AU - Munasinghe, Jeeva
AU - Wang, Hongsheng
AU - Kovalchuk, Alexander L.
AU - Kothari, Parul H.
AU - Fermaintt, Charles S.
AU - Atkinson, John P.
AU - Perrino, Fred W.
AU - Yan, Nan
AU - Morse, Herbert C.
N1 - Funding Information:
We thank members of Yan and Morse laboratories for helpful discussions. This work is supported by the NIH (AR067135 to N.Y., AI116725 to F.W.P.), Alliance for Lupus Foundation (N.Y.), the Robert G. Clark Family and Clayco Corporation, and in part by the Intramural Research Program of the NIH, NIAID. Private donations from Cure CRV Research, Energy 4A Cure Foundation, the Robert G. Clark Family and Clayco Corporation (P.H.K., J.P.A.) and NIH/NHLB1 HL083822 (PHK). None of the funders had a role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.
Publisher Copyright:
© 2017 Elsevier Ltd
PY - 2017/7
Y1 - 2017/7
N2 - TREX1/DNASE III, the most abundant 3′-5′ DNA exonuclease in mammalian cells, is tail-anchored on the endoplasmic reticulum (ER). Mutations at the N-terminus affecting TREX1 DNase activity are associated with autoimmune and inflammatory conditions such as Aicardi-Goutières syndrome (AGS). Mutations in the C-terminus of TREX1 cause loss of localization to the ER and dysregulation of oligosaccharyltransferase (OST) activity, and are associated with retinal vasculopathy with cerebral leukodystrophy (RVCL) and in some cases with systemic lupus erythematosus (SLE). Here we investigate mice with conditional expression of the most common RVCL mutation, V235fs, and another mouse expressing a conditional C-terminal mutation, D272fs, associated with a case of human SLE. Mice homozygous for either mutant allele express the encoded human TREX1 truncations without endogenous mouse TREX1, and both remain DNase active in tissues. The two mouse strains are similar phenotypically without major signs of retinal, cerebral or renal disease but exhibit striking elevations of autoantibodies in the serum. The broad range of autoantibodies is primarily against non-nuclear antigens, in sharp contrast to the predominantly DNA-related autoantibodies produced by a TREX1-D18N mouse that specifically lacks DNase activity. We also found that treatment with an OST inhibitor, aclacinomycin, rapidly suppressed autoantibody production in the TREX1 frame-shift mutant mice. Together, our study presents two new mouse models based on TREX1 frame-shift mutations with a unique set of serologic autoimmune-like phenotypes.
AB - TREX1/DNASE III, the most abundant 3′-5′ DNA exonuclease in mammalian cells, is tail-anchored on the endoplasmic reticulum (ER). Mutations at the N-terminus affecting TREX1 DNase activity are associated with autoimmune and inflammatory conditions such as Aicardi-Goutières syndrome (AGS). Mutations in the C-terminus of TREX1 cause loss of localization to the ER and dysregulation of oligosaccharyltransferase (OST) activity, and are associated with retinal vasculopathy with cerebral leukodystrophy (RVCL) and in some cases with systemic lupus erythematosus (SLE). Here we investigate mice with conditional expression of the most common RVCL mutation, V235fs, and another mouse expressing a conditional C-terminal mutation, D272fs, associated with a case of human SLE. Mice homozygous for either mutant allele express the encoded human TREX1 truncations without endogenous mouse TREX1, and both remain DNase active in tissues. The two mouse strains are similar phenotypically without major signs of retinal, cerebral or renal disease but exhibit striking elevations of autoantibodies in the serum. The broad range of autoantibodies is primarily against non-nuclear antigens, in sharp contrast to the predominantly DNA-related autoantibodies produced by a TREX1-D18N mouse that specifically lacks DNase activity. We also found that treatment with an OST inhibitor, aclacinomycin, rapidly suppressed autoantibody production in the TREX1 frame-shift mutant mice. Together, our study presents two new mouse models based on TREX1 frame-shift mutations with a unique set of serologic autoimmune-like phenotypes.
UR - http://www.scopus.com/inward/record.url?scp=85015429704&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85015429704&partnerID=8YFLogxK
U2 - 10.1016/j.jaut.2017.03.001
DO - 10.1016/j.jaut.2017.03.001
M3 - Article
C2 - 28325644
AN - SCOPUS:85015429704
VL - 81
SP - 13
EP - 23
JO - Journal of Autoimmunity
JF - Journal of Autoimmunity
SN - 0896-8411
ER -